SCHEMBL1419475

SCHEMBL1419475

CCCCCCCCCCCCCCCCNC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.51
NAAA Q02083 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
CHRM2 P08172 1/20 0.48
ADRA2A P08913 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
DRD1 P21728 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
CYP2C19 P33261 1/20 0.48
ADRA1A P35348 1/20 0.48
DRD3 P35462 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
DNM1 Q05193 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2029653 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL9655480 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1420133 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL2027019 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1419815 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1419654 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL2029786 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1419852 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1419840 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA
SCHEMBL1419591 1.00 CASP2 (0.51) CASP2NAAATDP1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110130327-A1 Multi-Arm Amines and Uses Thereof MARINA BIOTECH, INC. (US) 2011-06-02 US claimed
EP-0413405-A2 Use of amide complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1991-02-20 EP claimed
US-20110130327-A1 Multi-Arm Amines and Uses Thereof MARINA BIOTECH, INC. (US) 2011-06-02 US disclosed
EP-2296711-A2 MULTI-ARM AMINES AND USES THEREOF MDRNA, Inc. (US) 2011-03-23 EP disclosed
WO-2009148955-A2 MULTI-ARM AMINES AND USES THEREOF MDRNA, INC (US) 2009-12-10 WO disclosed
US-5399340-A Organ-specific nuclear magnetic resonance diagnosis SCHERING AKTIENGESELLSCHAFT (DE) 1995-03-21 US disclosed
EP-0413405-A2 Use of amide complex compounds SCHERING AKTIENGESELLSCHAFT (DE) 1991-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130327-A1 Multi-Arm Amines and Uses Thereof SNRPE, SNRPA, ADAR CASP2 3037/4885NAAA 997/4885TDP1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.